

**Drugs and Therapeutics (D & T) Committee**  
**Drugs Under Review for:**  
**June 14, 2017**

<b>Drug Name</b>	<b>Review Type</b>	<b>Class</b>	<b>Manufacturer</b>
Soliqua	New Drug Initial Review	Diabetes	Sanofi Pharmaceuticals
Exondys 51	New Drug Initial Review	Duchenne Muscular Dystrophy	Sarepta Therapeutics
Ocrevus	New Drug Initial Review	Relapsing/Remitting and Primary Progressive Multiple Sclerosis	Genentech
Xermelo	New Drug Initial Review	Carcinoid Syndrome Induced Diarrhea	Lexicon Pharmaceuticals
Bevespi Aerosphere	New Drug Initial Review	COPD	AstraZeneca
Utibron	New Drug Initial Review	COPD	Sunovion Pharmaceuticals
Spinraza	New Drug initial Review	Spinal Muscular Atrophy	Biogen
Jardiance	New Drug initial Review	Type 2 Diabetes	Boehringer-Ingelheim Pharmaceuticals
Dupixent	New Drug Initial Review	Atopic Dermatitis	Sanofi
Invega Trinza	New Drug Appeal	Long Acting Atypical Anti-psychotic	Janssen Pharmaceutical, Inc
Dyanavel XR	New Drug Appeal	ADHD Treatment	Tris Pharma
Granix	New Drug Appeal	Severe Neutropenia	Teva Pharmaceuticals
Pertzye	PDL Appeal	Pancreatic Enzyme	Digestive Care
Quillichew ER	PDL Appeal	ADHD Treatment	Pfizer, Inc.
Quillivant XR	PDL Appeal	ADHD Treatment	Pfizer, Inc.
Lyrica	PDL Appeal	Neuropathic Pain/Seizure Disorder	Pfizer, Inc.